Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.56 |
| ▸ | PRKCG | P05129 | 5/20 | 0.56 |
| ▸ | PRKCB | P05771 | 5/20 | 0.56 |
| ▸ | PRKCA | P17252 | 5/20 | 0.56 |
| ▸ | PRKCH | P24723 | 5/20 | 0.56 |
| ▸ | PRKCI | P41743 | 5/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.56 |
| ▸ | PRKACA | P17612 | 2/20 | 0.56 |
| ▸ | PRKACG | P22612 | 2/20 | 0.56 |
| ▸ | PRKACB | P22694 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31615194 | 1.00 | NPC1 (0.61) | NPC1RAB9APRKD3PRKCGPRKCB | |
| SCHEMBL29415921 | 0.92 | PRKD3 (0.62) | NPC1RAB9APRKD3PRKCGPRKCB | |
| SCHEMBL78989 | 0.92 | PRKD3 (0.62) | NPC1RAB9APRKD3PRKCGPRKCB | |
| SCHEMBL3959789 | 0.90 | PRKD3 (0.61) | NPC1RAB9APRKD3PRKCGPRKCB | |
| SCHEMBL6417753 | 0.81 | PRKD3 (0.56) | NPC1RAB9APRKD3PRKCGPRKCB | |
| SCHEMBL3908537 | 0.81 | PRKD3 (0.59) | NPC1RAB9APRKD3PRKCGPRKCB | |
| SCHEMBL1155579 | 0.80 | KDR (0.59) | NPC1RAB9APRKD3PRKCGPRKCB | |
| SCHEMBL15758300 | 0.79 | PRKCB (0.64) | NPC1RAB9APRKD3PRKCGPRKCB | |
| SCHEMBL12424814 | 0.78 | KDR (0.54) | NPC1RAB9APRKD3PRKCGPRKCB | |
| SCHEMBL2986726 | 0.78 | PRKD3 (0.53) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304663-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2009-12-10 | — | — | US | claimed |
| EP-1786448-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | Imperial Innovations Limited (GB) | 2007-05-23 | — | — | EP | claimed |
| WO-2006018633-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2006-02-23 | — | — | WO | claimed |
| US-20050075276-A1 | Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses | RUDD CHRISTOPHER (US) | 2005-04-07 | — | — | US | claimed |
| EP-2125683-B1 | 3-BENZOFURANYL-4-INDOLYL-MALEIMIDES AS POTENT GSK-3 INHIBITORS FOR NEURODEGENERATIVE DISORDERS | UNIV ILLINOIS (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8207216-B2 | Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100105745-A1 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-01-07 | — | — | US | disclosed |
| US-20090304663-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| EP-2125683-A1 | 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS | The Board of Trustees of the University of Illinois (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7476676-B2 | Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3β | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| WO-2002010158-A3 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2002-05-16 | — | — | WO | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | GSK3B, GSK3A, GSKIP | NPC1 3630/4885RAB9A 4004/4885PRKD3 941/4885 |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | NPC1 3465/4885RAB9A 3977/4885PRKD3 142/4885 |
| US-20100105745-A1 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta | GSK3B, GSK3A, GSKIP | NPC1 4150/4885RAB9A 3465/4885PRKD3 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.